shutterstock-71191654-web
Morphart Creation / Shutterstock.com
3 March 2015Americas

AstraZeneca boosts respiratory unit with Actavis deal

AstraZeneca has closed a deal that will see it acquire the rights to Actavis’s branded respiratory drugs business in the US and Canada, it was announced today (March 3).

The British company has gained the rights to develop and commercialise respiratory drugs Tudorza Pressair (aclidinium bromide inhalation powder) and Daliresp (roflumilast) in the North American countries.

Tudorza Pressair is a twice-daily inhaler that treats symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Daliresp is a once-daily tablet that prevents against the worsening of COPD symptoms.

Under the agreement, AstraZeneca has also been granted development rights in the US and Canada for LAS40464, a fixed dose combination of aclidinium bromide and long acting beta agonist formoterol fumarate in a dry powder inhaler, which is marketed in the EU under the brand name Duaklir Genuair.

AstraZeneca will pay Actavis $600 million when the transaction has been completed and has agreed to pay “low single-digit” royalties above an agreed revenue threshold.

In July last year, AstraZeneca added to its respiratory portfolio with the acquisition of Barcelona-based Almirall, granting it the rights to market inhalation powder Eklira (aclidinium) and Duaklir in the EU.


More on this story

Americas
5 May 2016   AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

More on this story

Americas
5 May 2016   AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.